目的 探讨乌司他丁注射液联合灯盏花素注射液治疗病毒性心肌炎的临床疗效。方法 选取2016年3月-2017年7月上海市浦东医院收治的病毒性心肌炎患者86例为研究对象，所有患者采用Excel表法随机分为对照组和治疗组，每组各43例。对照组静脉滴注灯盏花素注射液，10 mg加入到5%葡萄糖注射液250 mL中，1次/d。治疗组在对照组的基础上静脉滴注乌司他丁注射液，20万单位加入到0.9%氯化钠注射液100 mL中，2次/d。两组患者均持续治疗14 d。观察两组的临床疗效，比较两组的心脏损伤标志物水平和血清炎症因子水平。结果 治疗后，对照组和治疗组的总有效率分别为81.4%、93.0%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清肌酸激酶（CK）、肌酸激酶同工酶（CK-MB）、天门冬氨酸氨基转移酶（AST）、心肌肌钙蛋白I（cTnI）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组这些心脏损伤标志物水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）水平显著下降，超氧化物歧化酶（SOD）水平显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组这些血清炎症因子水平明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 乌司他丁注射液联合灯盏花素注射液治疗病毒性心肌炎具有较好的临床疗效，可改善心脏损伤，降低炎症水平，增强心肌功能，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Ulinastatin Injection combined with Breviscapine Injection in treatment of viral myocarditis. Methods Patients (86 cases) with viral myocarditis in Shanghai Pudong Hospital from March 2016 to July 2017 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were iv administered with Breviscapine Injection, 10 mg added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were iv administered with Ulinastatin Injection on the basis of the control group, 200 000 U added into normal saline 100 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the levels of cardiac damage markers and serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.4% and 93.0%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of CK, CK-MB, AST, and cTnI in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And levels of cardiac damage markers in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of TNF-α and IL-6 in two groups were significantly decreased, but the levels of SOD in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And serum inflammatory factors in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Ulinastatin Injection combined with Breviscapine Injection has clinical curative effect in treatment of viral myocarditis, can improve cardiac damage, decrease inflammation level, and enhance myocardial function, which has a certain clinical application value.